Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fevipiprant - Novartis

Drug Profile

Fevipiprant - Novartis

Alternative Names: NVP-QAW-039; QAW-039; QAW-39A; QAW39-A2107

Latest Information Update: 23 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Acetic acids; Anti-inflammatories; Antiallergics; Antiasthmatics; Pyridines; Pyrroles; Skin disorder therapies
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Allergic asthma; Asthma; Nasal polyps
  • Phase II Atopic dermatitis; Chronic obstructive pulmonary disease
  • No development reported Allergic rhinitis

Most Recent Events

  • 05 Dec 2019 Novartis announces intention to launch Fevipiprant for Asthma
  • 04 Nov 2019 Novartis completes a phase III trial in Allergic asthma in USA, Argentina, Australia, Austria, Belgium, China, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hungary, Iceland, Ireland, Lithuania, Luxembourg, Philippines, Poland, Romania, Singapore, Spain, Switzerland, United Kingdom, Vietnam and Latvia (NCT02555683)
  • 02 Aug 2019 Novartis completes a phase III trial for Asthma (Adjunctive treatment, In adolescents, In children, In the elderly, In adults) in USA, Canada, Netherlands, Slovakia, Spain, Czech Republic, Italy, Greece, Argentina, India, Israel, Japan, Lebanon, Malaysia, Mexico, Russia, Serbia, South Africa, Taiwan (PO) (NCT02563067) (EudraCT2015-003172-67)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top